Boston Scientific is a high-quality medical device maker with 17% margins, a 13.3x forward P/E and insider buying of $9.3M, but it sits in a confirmed downtrend after a 60% drawdown with weak growth and a put/call ratio of 6.03.
Thesis pillars
- High Quality Device Margins↓Deteriorating
- Attractive Valuation Peg↓Deteriorating
- Insider Buying Signal↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Feb 17, 2026
Boston Scientific Corporation (BSX) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $45.82, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source components; Analyst target reached - limited upside remaining.
Boston Scientific develops, manufactures, and markets medical devices across two reportable segments — MedSurg and Cardiovascular — for use in interventional cardiology, electrophysiology, urology, endoscopy, neuromodulation, and oncology procedures sold in 127 countries.... Read more
Hold if already holding. Not a fresh buy at $45.82, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source components; Analyst target reached - limited upside remaining. Chart setup: Death cross but MACD improving, RSI 56. Maintain position. Not compelling to add more. Score 5.3/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 97d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Boston Scientific Corporation
About Boston Scientific Corporation
Boston Scientific's two reportable segments — MedSurg and Cardiovascular — serve hospitals and clinics in 127 countries, with international net sales at 36% of global net sales in 2025. The FARAPULSE Pulsed Field Ablation System, launched in 2024, became the predominant component of Electrophysiology business-unit revenue following FDA expanded labeling approval for persistent atrial fibrillation in the second quarter of 2025. On January 15, 2026, the company announced a definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion, to be funded largely through approximately $11 billion in new debt.
Boston Scientific markets a broad range of single-use and implantable devices across endoscopy, urology, neuromodulation, ICVT, WATCHMAN left atrial appendage closure, electrophysiology, CRM, and interventional oncology. Sales flow primarily through dedicated direct sales forces, supplemented by distributors in markets where direct presence is not cost-effective, reaching hospitals, clinics, outpatient facilities, and medical offices in 127 countries. In China, the company faces competition from domestic device manufacturers that may benefit from local-supplier preferences in tender processes. Certain materials and components are purchased from single sources due to quality considerations, expertise, or regulatory constraints, and the 10-K acknowledges ongoing risk from certain vendors that could result in increased costs or supply interruption. The pending Penumbra acquisition would raise total debt well above the $11.436 billion outstanding as of December 31, 2025, increasing financial leverage during the integration period.
Show full overview
Single-source component supply poses a structural manufacturing risk: certain items are custom-made or sourced from a single supplier due to quality, expertise, cost, or regulatory constraints — a situation the 10-K describes as carrying ongoing vendor risk. Boston Scientific's global manufacturing footprint and tariff exposure compound this: the company cites U.S. trade tariff and policy uncertainty as a factor that may affect its ability to source and manufacture products cost-effectively, and faces potential retaliatory measures that could limit access to international markets. No specific mitigation timeline is disclosed beyond the existing supplier resiliency program.
See also: Healthcare · Medical Devices
From Boston Scientific Corporation's most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated Nov 5, 2026Recent Developments — Boston Scientific Corporation
Latest news
- NEWS CCORF Maintains Buy Rating and $48 Price Target for Boston Scientific — fiscal.ai Nov 5, 2026 positive
- NEWS Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years — benzinga Nov 4, 2026 positive
- NEWS Boston Scientific and Blackstone Life Sciences Announce $455 Million Co-Funding Agreement — fiscal.ai Nov 3, 2026 positive
- NEWS Why Boston Scientific (BSX) shares are plunging today - Yahoo Finance — Yahoo Finance Oct 29, 2026 negative
- NEWS Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack — The Motley Fool Oct 28, 2026 negative
Latest item Nov 5, 2026 · Generated 2026-11-05T11:54:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicinternational net sales36%10-K Item 1A: 'International net sales accounted for 36 percent of our global net sales in 2025'
- HIGHSuppliersingle-source components10-K Item 1: 'certain materials and components are purchased from single sources due to quality considerations, expertise, costs or constraints resulting from regulatory requirements'
- MEDIUMProductFARAPULSE10-K Item 1: 'FARAPULSE™ PFA System ... the predominant component of our Electrophysiology business unit and revenue'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $45.82, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source components; Analyst target reached - limited upside remaining. Chart setup: Death cross but MACD improving, RSI 56. Maintain position. Not compelling to add more. Analyst target $44.64 reached (−2.6%), stop $42.61 (−7.5%), A.R:R -0.2:1. Score 5.3/10, moderate confidence.
Analyst target $44.64 reached (−2.6% from $45.82); no take-profit level is published. Analyst target $44.64 reached (−2.6%), stop $42.61 (−7.5%), A.R:R -0.2:1. Stop-loss: $42.61.
Concentration risk — Supplier: single-source components; Analyst target reached - limited upside remaining; Earnings estimates trending DOWN.
Boston Scientific Corporation trades at a P/E of 19.3 (forward 14.6). TrendMatrix value score: 6.6/10. Verdict: Hold.
37 analysts rate BSX, with a consensus score of 3.8/5. 28 analysts publish price targets averaging $50.
What does Boston Scientific Corporation do?Boston Scientific develops, manufactures, and markets medical devices across two reportable segments — MedSurg and...
Boston Scientific develops, manufactures, and markets medical devices across two reportable segments — MedSurg and Cardiovascular — for use in interventional cardiology, electrophysiology, urology, endoscopy, neuromodulation, and oncology procedures sold in 127 countries. International net sales represented 36% of global net sales in 2025; outstanding debt was $11.436 billion as of December 31, 2025, with a pending ~$14.5 billion acquisition of Penumbra announced January 15, 2026.